Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +1.66%100 3-Year ROIIC % is 12.41 as of Jun. 2025, which is 73% below its 10-year median of 46.63. GuruFocus rates OCSE:CHEMM with a GF Score™ of 100/100 and a GF Value™ of kr551.78 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 796 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 63.44% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ChemoMetec AS's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 12.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ChemoMetec AS's 3-Year ROIIC % or its related term are showing as below:
OCSE:CHEMM's 3-Year ROIIC % is ranked better than 63.44% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs OCSE:CHEMM: 12.41
ChemoMetec AS (OCSE:CHEMM) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ChemoMetec AS 3-Year ROIIC % Related Terms
ChemoMetec AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, ChemoMetec AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ChemoMetec AS (OCSE:CHEMM) has a 3-Year ROIIC % of 12.41 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ChemoMetec AS and its competitors. This is 73% below median its historical median of 46.63. Over the past decade, ChemoMetec AS's 3-Year ROIIC % has ranged from 12.41 to 120.83. According to the industry distribution chart, ChemoMetec AS ranks #291 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 36.6%.
Is ChemoMetec AS's 3-Year ROIIC % too high?
ChemoMetec AS's current 3-Year ROIIC % of 12.41 is 73% below median its 10-year median of 46.63. Over the past 10 years, this metric has ranged from a low of 12.41 to a high of 120.83. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. ChemoMetec AS's value of 12.41 is 666% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #291 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #291 out of 796 companies for 3-Year ROIIC %. This puts ChemoMetec AS in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. ChemoMetec AS's value of 12.41 is 666% above this benchmark. Historically, ChemoMetec AS's own 3-Year ROIIC % has ranged from 12.41 to 120.83 over the past decade. While the company's 10-year median is 46.63 vs. the industry median of 1.62, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current 3-Year ROIIC % of 12.41 is 666% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current 3-Year ROIIC % is 12.41, which is 73% below median its own 10-year median of 46.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr551.78, compared to a current price of kr417.40 — trading 24.4% below its estimated fair value. The current 3-Year ROIIC % is 12.41, which is 73% below median its 10-year median of 46.63 and 666% above the Medical Devices & Instruments industry median of 1.62. ChemoMetec AS's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current 3-Year ROIIC % is 12.41 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr417.40 is trading 24.4% below its estimated GF Value™ of kr551.78.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
3-Year ROIIC %: 12.41 (73% below median its 10-year median of 46.63)
GF Value™: kr551.78 vs. price of kr417.40 (24.4% below fair value)
Industry Position: 666% above the Medical Devices & Instruments median (#291 of 796)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
100GF Score
Get the complete analysis for OCSE:CHEMM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
